← Scroll for more →
Financial Statements — NYAX
Balance Sheet
(in millions USD)| Metric | Q4 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 319.54 | 83.13 | 61.91 | 38.39 | 31.05 | 33.88 |
| Inventory | 28.59 | 19.77 | 20.31 | 20.56 | 22.92 | 23.81 |
| Total Current Assets | 620.16 | 287.66 | 290.85 | 203.41 | 177.86 | 150.46 |
| Total Non-current Assets | 232.47 | 145.24 | 143.84 | 120.45 | 83.96 | 80.03 |
| Total Assets | 852.64 | 432.89 | 434.69 | 323.86 | 261.83 | 230.49 |
| Total Current Liabilities | 274.42 | 219.48 | 232.17 | 203.78 | 151.23 | 110.21 |
| Total Non-current Liabilities | 347.21 | 48.17 | 43.83 | 22.49 | 10.65 | 15.65 |
| Total Liabilities | 621.62 | 267.65 | 276.00 | 226.27 | 161.87 | 125.85 |
| Retained Earnings | (19.64) | (63.31) | (70.24) | (65.58) | (62.58) | (56.55) |
| Total Stockholder Equity | 231.02 | 165.25 | 158.69 | 97.59 | 99.96 | 104.64 |
← Scroll for more columns →
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Total Revenue | 78.09 | 56.16 |
| Cost of Revenue* | 43.50 | 35.30 |
| Gross Profit | 34.59 | 20.86 |
| Research & Development | 6.42 | 4.97 |
| Selling, General & Admin | 23.82 | 17.54 |
| Total Operating Expenses* | 33.68 | 24.56 |
| Operating Income | 0.91 | (3.71) |
| Pretax Income | (2.69) | (3.75) |
| Tax Provision | 0.32 | 0.23 |
| Net Income | (3.01) | (3.97) |
| Basic EPS | (0.08) | (0.12) |
| Diluted EPS | (0.08) | (0.12) |
← Scroll for more columns →
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Operating Cash Flow | 9.19 | (1.66) |
| Investing Cash Flow | (20.52) | (5.97) |
| Financing Cash Flow | 4.27 | 4.91 |
← Scroll for more columns →